Cargando…

Nuclear AhR and membranous PD-L1 in predicting response of non-small cell lung cancer to PD-1 blockade

Detalles Bibliográficos
Autores principales:	Han, Si-Chong, Wang, Gui-Zhen, Yang, Ya-Ning, Fang, Wen-Feng, Sun, Bei-Bei, Zhang, Jian-Dong, Zhou, Hua-Qiang, Zhang, Li, Wang, Yan, Zhou, Guang-Biao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225463/ https://www.ncbi.nlm.nih.gov/pubmed/37246200 http://dx.doi.org/10.1038/s41392-023-01416-5

Ejemplares similares

The Landscape of AhR Regulators and Coregulators to Fine-Tune AhR Functions
por: Gargaro, Marco, et al.
Publicado: (2021)

Serotonin Modulates AhR Activation by Interfering with CYP1A1-Mediated Clearance of AhR Ligands
por: Manzella, Christopher R., et al.
Publicado: (2020)

Coactivator Recruitment of AhR/ARNT1
por: Endler, Alexander, et al.
Publicado: (2014)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

AhR promotes phosphorylation of ARNT isoform 1 in human T cell malignancies as a switch for optimal AhR activity
por: Bourner, Luke A., et al.
Publicado: (2022)

Accumulation of dysfunctional tumor-infiltrating PD-1+ DCs links PD-1/PD-L1 blockade immunotherapeutic response in cervical cancer
por: Wang, Yu-meng, et al.
Publicado: (2022)

AhR and IDO1 in pathogenesis of Covid-19 and the “Systemic AhR Activation Syndrome:” a translational review and therapeutic perspectives
por: Turski, Waldemar A., et al.
Publicado: (2020)

Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy
por: Gao, Hannan, et al.
Publicado: (2020)

Blockade of IDO-Kynurenine-AhR Axis Ameliorated Colitis-Associated Colon Cancer via Inhibiting Immune Tolerance
por: Zhang, Xin, et al.
Publicado: (2021)

Tumor-Suppressive Functions of the Aryl Hydrocarbon Receptor (AhR) and AhR as a Therapeutic Target in Cancer
por: Elson, Daniel J., et al.
Publicado: (2023)

Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
por: Zhang, Min, et al.
Publicado: (2019)

Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle
por: Zhuang, Yuan, et al.
Publicado: (2020)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Activation of AhR with nuclear IKKα regulates cancer stem-like properties in the occurrence of radioresistance
por: Yan, Bin, et al.
Publicado: (2018)

Bidirectional talk between AhR and Oct4
por: Kang, Bo, et al.
Publicado: (2015)

AhR signaling pathways and regulatory functions
por: Larigot, Lucie, et al.
Publicado: (2018)

Epigenetic Regulations of AhR in the Aspect of Immunomodulation
por: Wajda, Anna, et al.
Publicado: (2020)

Mitochondrial activity and oxidative stress functions are influenced by the activation of AhR-induced CYP1A1 overexpression in cardiomyocytes
por: Zhou, Bing, et al.
Publicado: (2017)

Genetic biomarkers for PD-1/PD-L1 blockade therapy
por: Kataoka, Keisuke, et al.
Publicado: (2016)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

AhR-Mediated, Non-Genomic Modulation of IDO1 Function
por: Pallotta, Maria Teresa, et al.
Publicado: (2014)

The Coevolution of IDO1 and AhR in the Emergence of Regulatory T-Cells in Mammals
por: Grohmann, Ursula, et al.
Publicado: (2015)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
por: Jing, Wang, et al.
Publicado: (2016)

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
por: Ren, Daixi, et al.
Publicado: (2020)

Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
por: Jiang, Youhai, et al.
Publicado: (2020)

Interaction between AhR and HIF-1 signaling pathways mediated by ARNT/HIF-1β
por: Zhang, Mengdi, et al.
Publicado: (2022)

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
por: Zhao, Xuan, et al.
Publicado: (2022)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Ethyl Caffeate Can Inhibit Aryl Hydrocarbon Receptor (AhR) Signaling and AhR-Mediated Potentiation of Mast Cell Activation
por: Nguyen, Phuc-Tan, et al.
Publicado: (2023)

Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
por: Sun, Jin-Yu, et al.
Publicado: (2020)

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
por: Wu, Mengling, et al.
Publicado: (2022)

M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer
por: Zhao, Rui, et al.
Publicado: (2020)

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
por: Hamanishi, Junzo, et al.
Publicado: (2016)

Oncolytic virus and PD-1/PD-L1 blockade combination therapy
por: Chen, Chun-Yu, et al.
Publicado: (2018)

Drug response to PD-1/PD-L1 blockade: based on biomarkers
por: Chen, Qi, et al.
Publicado: (2018)

Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
por: Zhao, Bin, et al.
Publicado: (2020)

Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas
por: Katsuya, Hiroo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tmnh1ct8u07p2icpeq99me32qj